Similar articles

• A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease.

  Montastruc JL, Rascol O, Senard JM, Rascol A. Montastruc JL, et al. J Neurol Neurosurg Psychiatry. 1992 Jul;55(7):630-1. doi: 10.1136/jnnp.55.7.630-a. J Neurol Neurosurg Psychiatry. 1992. PMID: 1386383 Free PMC article. No abstract available.
• Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.

  Addy C, Assaid C, Hreniuk D, Stroh M, Xu Y, Herring WJ, Ellenbogen A, Jinnah HA, Kirby L, Leibowitz MT, Stewart RM, Tarsy D, Tetrud J, Stoch SA, Gottesdiener K, Wagner J. Addy C, et al. J Clin Pharmacol. 2009 Jul;49(7):856-64. doi: 10.1177/0091270009336735. Epub 2009 Jun 2. J Clin Pharmacol. 2009. PMID: 19491335 Clinical Trial.
• NMDA antagonists as Parkinson's disease therapy: disseminating the evidence.

  Majláth Z, Vécsei L. Majláth Z, et al. Neurodegener Dis Manag. 2014;4(1):23-30. doi: 10.2217/nmt.13.77. Neurodegener Dis Manag. 2014. PMID: 24640976
• Insights into structure-activity relationships and CNS therapeutic applications of NR2B selective antagonists.

  Beinat C, Banister S, Moussa I, Reynolds AJ, McErlean CS, Kassiou M. Beinat C, et al. Curr Med Chem. 2010;17(34):4166-90. doi: 10.2174/092986710793348572. Curr Med Chem. 2010. PMID: 20939817 Review.
• Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease.

  Koutsilieri E, Riederer P. Koutsilieri E, et al. Parkinsonism Relat Disord. 2007;13 Suppl 3:S329-31. doi: 10.1016/S1353-8020(08)70025-7. Parkinsonism Relat Disord. 2007. PMID: 18267259 Review.